Catalyst Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
CORAL GABLES, Fla., Jan. 04, 2024 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (“Catalyst” or the “Company”) (Nasdaq: CPRX) announced today…
Pharmaceuticals, Biotechnology and Life Sciences
CORAL GABLES, Fla., Jan. 04, 2024 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (“Catalyst” or the “Company”) (Nasdaq: CPRX) announced today…
Reported updated data from ongoing Phase 1b trial in kidney transplantation demonstrating tegoprubart treatment successfully prevented kidney transplant rejection and…
Financing Led by Leading U.S. Life Sciences-focused InvestorsPETACH TIKVA, Israel, Jan. 04, 2024 (GLOBE NEWSWIRE) — PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or…
CHARLOTTESVILLE, Va., Jan. 04, 2024 (GLOBE NEWSWIRE) — Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel…
Partnership Will Utilize Foresight’s Ultra-Sensitive MRD Technology to Identify Patients for Enrollment in Allogene’s ALPHA3 Trial SAN FRANCISCO and BOULDER,…
LEXINGTON, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) — Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic…
WATERTOWN, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) — Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical…
RADNOR, Pa., Jan. 04, 2024 (GLOBE NEWSWIRE) — Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing…
Plans to advance diverse pipeline of programs in oncology and metabolic diseases Anticipates key proof-of-concept readouts for TERN-701 (CML) and…
Four Core Programs Leverage Unique Attributes in Product Development and Trial Design to Demonstrate the Unmatched Potential of an Allogeneic…